Posted by Michael Wonder on 04 Jun 2021
FDA authorises lower 1,200 mg intravenous and subcutaneous dose of Regen-COV (casirivimab and imevimab) antibody cocktail to treat patients with COVID-19
4 June 2021 - EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalisation or death by 70%.
Regeneron Pharmaceuticals today announced the U.S. FDA updated the emergency use authorisation for Regen-COV, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorised.
